Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 15;122(2):304-11.
doi: 10.1002/cncr.29615. Epub 2015 Dec 7.

Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia

Jane E Churpek  1   2   3 , Rafael Marquez  2 , Barbara Neistadt  2 , Kimberly Claussen  2 , Ming K Lee  4 , Matthew M Churpek  2   5 , Dezheng Huo  5 , Howard Weiner  2 , Mekhala Bannerjee  2 , Lucy A Godley  1   2   3 , Michelle M Le Beau  2   3 , Colin C Pritchard  6 , Tom Walsh  4 , Mary-Claire King  4 , Olufunmilayo I Olopade  1   2   3 , Richard A Larson  2   3
Affiliations

Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia

Jane E Churpek et al. Cancer. .

Abstract

Background: Risk factors for the development of therapy-related leukemia (TRL), an often lethal late complication of cytotoxic therapy, remain poorly understood and may differ for survivors of different malignancies. Survivors of breast cancer (BC) now account for the majority of TRL cases, making the study of TRL risk factors in this population a priority.

Methods: Subjects with TRL after cytotoxic therapy for a primary BC were identified from the TRL registry at The University of Chicago. Those with an available germline DNA sample were screened with a comprehensive gene panel covering known inherited BC susceptibility genes. Clinical and TRL characteristics of all subjects and those with identified germline mutations were described.

Results: Nineteen of 88 survivors of BC with TRL (22%) had an additional primary cancer and 40 of the 70 survivors with an available family history (57%) had a close relative with breast, ovarian, or pancreatic cancer. Of the 47 subjects with available DNA, 10 (21%) were found to carry a deleterious inherited mutation in BRCA1 (3 subjects; 6%), BRCA2 (2 subjects; 4%), TP53 (tumor protein p53) (3 subjects; 6%), CHEK2 (checkpoint kinase 2) (1 subject; 2%), and PALB2 (partner and localizer of BRCA2) (1 subject; 2%).

Conclusions: Survivors of BC with TRL have personal and family histories suggestive of inherited cancer susceptibility and frequently carry germline mutations in BC susceptibility genes. The data from the current study support the role of these genes in TRL risk and suggest that long-term follow-up studies of women with germline mutations who are treated for BC and functional studies of the effects of heterozygous mutations in these genes on bone marrow function after cytotoxic exposures are warranted. Cancer 2016;122:304-311. © 2015 American Cancer Society.

Keywords: breast cancer; inherited; leukemia; therapy-related.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Inherited mutations in breast cancer susceptibility genes among 47 subjects with therapy-related leukemia
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abdulwahab A, Sykes J, Kamel-Reid S, Chang H, Brandwein JM. Therapy-related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis. Cancer. 2012;118(16):3962–7. - PubMed
    1. Kayser S, Dohner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117(7):2137–45. - PubMed
    1. Shivakumar R, Tan W, Wilding GE, Wang ES, Wetzler M. Biologic features and treatment outcome of secondary acute lymphoblastic leukemia--a review of 101 cases. Ann Oncol. 2008;19(9):1634–8. - PMC - PubMed
    1. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102(1):43–52. - PubMed
    1. Society AC. Cancer Facts & Figures 2014. Atlanta: American Cancer Society; 2014.

Publication types

MeSH terms

Substances

Supplementary concepts